3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Rectal Neoplasms
1
Pleural Effusion
1
Pleural Diseases
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Hematologic Diseases
1
Disease
1
Colorectal Neoplasms
1
Bone Marrow Diseases
1
Interventions
Cyclophosphamide
20
Brentuximab Vedotin
20
fludarabine
16
Lenalidomide
13
Rituximab
12
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
pirtobrutinib
6
Doxorubicin
6
Bortezomib
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
venetoclax
3
nilotinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Diseases
×
Clinical Laboratory Techniques
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled